← Leaderboards
David R Tabatadze
Zata Pharmaceuticals, Inc.
$6,231,294
Attributed
$6,231,294
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2014–21$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$6,231,294 · 6
By mechanism
R44$4,345,041 · 2
R43$1,886,253 · 4
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Property”
- Mitchell J Malone · Texas A&M Research Foundation$344,583,004
- Gary D Acton · University Of California-Davis$320,373,312
- Everette D Joseph · Howard University$250,079,293
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
Research focus
PropertyPlasmaTechnologyScale UpNucleic AcidsBiologicalLegal PatentProceduresSchemeToxic EffectChemistrySafetyPharmacologic SubstanceBloodBaseIn VivoIn VitroVirusPathogenAnalogBlood-Borne PathogensChargeInfectionLiquid Substance
Grant awards (9)
A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION$1,169,287
R44 · FY2021 · HL · contact PI
Highly Selective Pathogen Inactivators For Treatment of Convalescent Transfusion Plasma$717,598
R43 · FY2021 · HL · contact PI
A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION$1,010,910
R44 · FY2020 · HL · contact PI
A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION$780,492
R44 · FY2019 · HL · contact PI
New-Generation of Fluorescently-Labeled Charge-Neutralized Oligonucleotides as Probes for the Detection and Quantification of MicroRNAs and Oligonucleotide-Based Therapeutics in Biological Samples$402,225
R43 · FY2018 · GM · contact PI
SELF-NEUTRALIZING OLIGONUCLEOTIDES WITH ENHANCED CELLULAR UPTAKE$587,932
R44 · FY2017 · GM · contact PI
SELF-NEUTRALIZING OLIGONUCLEOTIDES WITH ENHANCED CELLULAR UPTAKE$796,420
R44 · FY2016 · GM · contact PI
AZIRIDINYL GROUPS CONTAINING POLYAMINES AS ANTI-PATHOGEN DEVICE FOR BLOOD PRODUCTS INTENDED FOR TRANSFUSION$402,588
R43 · FY2015 · HL · contact PI
SELF-NEUTRALIZING OLIGONUCLEOTIDES WITH ENHANCED CELLULAR UPTAKE$363,842
R43 · FY2014 · GM · contact PI